Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesda

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday&

Penguin Solutions jumped 7.7% after beating Q4 revenue/EPS estimates and issuing above-consensus FY2

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesd

Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-ma

Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's r

Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares rose 23.4% to $6.07 during Friday's pre-mark

Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday&

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Actuate Therapeutics (NASD

Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session

Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biopharmaceutical company focused on deve

- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall surv

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data s

Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACT

The combination strategy is designed to simultaneously block proliferative signaling through RAS inh

Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-s

Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall sur

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewi

Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-s

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the ana

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials i

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-st

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-st

B. Riley Securities analyst Mayank Mamtani initiates coverage on Actuate Therapeutics (NASDAQ:ACT

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.30) per share which beat the ana

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontli